The second metabolism of CME and FCME had anti-obesity action via the inhibition of adipogenesis and fat accumulation by modulating the reduction of adipogenesis-related factors, the enhancement of lipolysis-related factors and improved glucose tolerance and insulin activity, consequently reducing damage-associated liver enzymes. The gene discussed is INS; the disease is obesity disorder.